Zydus Lifesciences Enhances Transplant Outcomes with Innovative Therapy

The Indian pharmaceutical sector is witnessing a major advance. Zydus Lifesciences is launching ANVIMO, a cost-effective substitute for the prevention of Cytomegalovirus (CMV) disease in haematopoietic stem cell transplant (HSCT) and kidney transplant patients.

CMV is marked as a major post-transplant difficulty, often leading to graft failure, decreased survival, and extended hospital stays. Traditional treatments, such as ganciclovir and valganciclovir, have been linked to harmfulness and bone marrow destruction. However, Letermovir provides a safer and more effective alternative with fewer side effects, refining overall transplant results.

The monetary burden of post-transplant care in India has been a major distress, with CMV prophylaxis being a mainly costly concern. Imported modernized Letermovir 240 mg earlier costs over Rs. 5 lakh per month, limiting access for numerous patients. Zydus' launch of ANVIMO, in dosages of 240 and 480 mg, slashes costs by 91%, significantly enhancing affordability.

“The introduction of ANVIMO marks a new era in bone marrow transplant and kidney transplant care in India. By making this critical therapy affordable and accessible, we are reinforcing our commitment to delivering world-class healthcare solutions. Our mission is to ensure that transplant patients get access to affordable, life-saving treatment,” said Dr. Sharvil Patel, MD of Zydus Lifesciences.

By offering a reasonable alternative with verified bioequivalence to the reference drug, Zydus Lifesciences is transforming CMV prophylaxis in India, guaranteeing better survival rates and quality of life for transplant patients.